Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
Holding PROK?
Track your performance easily
PROK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.18 - $4.44
Previous CloseN/A
Volume58.77K
Average Volume (3M)505.82K
Market Cap
$484.24M
Enterprise Value$1.27B
Total Cash (Recent Filing)$20.56M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Apr 01, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding127,968,250
10 Day Avg. Volume502,066
30 Day Avg. Volume505,821
Standard Deviation0.23
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap2.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.65
Forecast
1Y Price Target
$3.00Price Target Upside80.72% Upside
Rating ConsensusHold
Number of Analyst Covering1
ProKidney News
PremiumCompany Announcements
ProKidney’s Progress in FDA Approval and Financial Health
PremiumCompany Announcements
ProKidney: Investor Update and Phase 3 Program ProgressBulls Say, Bears Say
Bulls Say
Financial StabilityCurrent cash balance funds operations into 2027.
Market PotentialRilparencel is a differentiated approach in diabetic CKD with blockbuster potential.
Regulatory ApprovalFDA confirmed that PROACT 1 could be sufficient to support a BLA submission and full approval.
Bears Say
Financial PerformanceTopline results for the PROACT 1 study are expected in 3Q27, beyond the company's current cash runway.
Market SentimentNeed for more de-risking data for the product to increase Street focus and shift sentiment.
Research And DevelopmentThe sample size of the most recent data from the REGEN-007 study is small.
---
Ownership Overview
Currently, No data available
---
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $1.18 and its highest was $4.44 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $484.24M.
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is Apr 01, 2025 which is in 81 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Nov 12, 2024. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.012.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -0.15.
How many shares outstanding does ProKidney have?
ProKidney has 127,968,250 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went down -4.651%.
Which hedge fund is a major shareholder of ProKidney?
Among the largest hedge funds holding ProKidney’s share is EntryPoint Capital, LLC. It holds ProKidney’s shares valued at 33K.
---
ProKidney Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (80.72% Upside)
$3.00 (80.72% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.09%
Trailing 12-Months
Company Description
ProKidney
Social Capital Suvretta Holdings Corp III is a blank check company.
---
PROK Company Deck
---
PROK Earnings Call
Q3 2023
0:00 / 0:00
---
PROK Stock 12 Month Forecast
Average Price Target
$3.00
▲(80.72% Upside)
Technical Analysis
Atossa Therapeutics
―
Curis
―
Fate Therapeutics
―
Kiniksa Pharmaceuticals
―
Rocket Pharmaceuticals
―
Xenon
―
Best Analysts Covering PROK
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-31.17%
reiterated a buy rating 4 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -31.17% per trade.
---